KONEXElectrical Equipment199290

Bio Protech

₩394▼ 1.25%2026-10-02 close

Market Cap

₩6.7B

Turnover

₩24,932

Volume

63 shares

Shares out.

17M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Global-Facing Medical Electrode Maker Trapped in KONEX Illiquidity

Bio Protech is an export-driven specialist manufacturer of ECG and SpO2 electrodes supplying global medtech leaders including GE Healthcare and Cardinal Health, yet extreme market illiquidity as a micro-cap KONEX listing remains the primary barrier to investor access.

1
Specialist manufacturer of ECG electrodes and SpO2 sensors with direct supply relationships established with GE Healthcare and Cardinal Health within global medtech supply chains
2
Export revenue share above 70%, with U.S. and China subsidiaries and full compliance with FDA, CE Mark, and ISO 13485 certifications meeting advanced-market regulatory requirements
3
2024 revenue of approximately KRW 25.1 billion per third-party data (NICE Credit Information; DART confirmation required), with approximately 102 employees
4
Global biosensors market projected to grow from approximately USD 32.3 billion in 2024 to USD 68.5 billion by 2034 at a CAGR of roughly 7.9% (GMI Insights), providing structural tailwinds
5
As a micro-cap KONEX listing with negligible daily trading value, the stock effectively precludes institutional and foreign investor participation and carries zero sell-side analyst coverage

Business structure

Bio Protech traces its origins to 1998, when it began R&D on ECG biosignal transmission sensors and became among the first companies from a developing country to enter a biosensor segment previously dominated entirely by imports from the U.S., Japan, and Europe.

The company converted to a corporation in May 2000 and subsequently relocated its headquarters to the Wonju Donghwa Advanced Medical Device Industrial Complex, where it maintains its production base today.

Its core product portfolio spans ECG electrodes (including tab electrodes), low-frequency stimulation pads (TENS), grounding electrodes for surgical use, high-frequency electrosurgical electrodes, and SpO2 sensors—covering the full spectrum of key disposable medical consumables.

Because most products are single-use disposables, the company benefits from recurring replacement demand dynamics.

Key customers include GE Healthcare and Cardinal Health, two of the world's largest medtech and distribution companies; the company also holds OEM supply contracts with 3M covering 16 Asian countries and a supply agreement with Japan's Kobayashi Medical Group.

To strengthen its global distribution footprint, Bio Protech operates a U.S. subsidiary in Los Angeles and a subsidiary in China. The company holds ISO 9001 and 13485 certifications, a CE Mark, and U.S. FDA registration, meeting entry requirements across all major advanced-market regulatory regimes.

It is classified under 'Electrical Equipment' by KRX, while FnGuide categorizes it under 'Medical Equipment and Services'—the actual business being disposable medical device manufacturing.

With approximately 102 employees and a dedicated corporate research institute, the company targets reinvestment of roughly 10% of revenues into R&D to deepen its in-house technology capabilities.

Recent trends

As of June 7, 2026, the share price stood at KRW 435, up 7.67% day-on-day, yet approximately 34% below the 52-week high of KRW 660 (per Hankyung market data).

The 52-week low was KRW 298, implying a wide price range of KRW 298–660 over the past year; however, this volatility primarily reflects structural illiquidity rather than active two-sided trading.

The reported daily trading value of KRW 1,292 on the reference date is effectively indistinguishable from a day of zero trading, and the market capitalization is so small it rounds to 0.0 trillion KRW.

Third-party employment data citing NICE Credit Information puts 2024 revenue at approximately KRW 25.1 billion (roughly USD 18 million at recent exchange rates), though this figure requires confirmation against Bio Protech's filed DART disclosures.

Paid-in capital of approximately KRW 11.2 billion suggests a seemingly stable capital structure relative to revenues, but profitability metrics such as operating margin and net income cannot be verified from publicly available sources.

KONEX-listed companies operate under lighter periodic disclosure requirements relative to KOSDAQ and KOSPI peers, further limiting the quality of information accessible to outside investors.

No significant new disclosures—such as major supply contract announcements or new customer wins—were identified within the scope of recent searches.

Outlook

The global biosensors market is projected by GMI Insights to expand from approximately USD 32.3 billion in 2024 to USD 68.5 billion by 2034 at a CAGR of roughly 7.9%, with Grand View Research similarly forecasting a USD 49.8 billion market by 2030 at a CAGR of 8.04%.

These projections imply structural demand growth for the ECG electrode and SpO2 sensor sub-markets that form the core of Bio Protech's revenues.

Global aging trends and rising chronic disease prevalence—particularly cardiovascular diseases and diabetes—represent the most powerful macro drivers underpinning durable long-term demand for these product categories.

Leveraging established partnerships with GE Healthcare and Cardinal Health, the company could potentially expand its supply footprint into emerging markets such as the Middle East and Southeast Asia, with its China subsidiary offering a platform for deeper Asian market penetration.

A sustained period of Korean won weakness would provide a favorable translation effect on the company's predominantly dollar-denominated export revenues.

On the other hand, no publicly confirmed plans for an upward listing to KOSDAQ or KOSPI have been identified, leaving any catalyst for meaningful liquidity improvement unclear.

Diversification of the new-product pipeline and timely adaptation to the digitalization wave in medical devices—including smart patches and wireless biosignal monitoring—remain critical medium- to long-term growth imperatives.

Bull factors

Validated Global Customer Base

Stable supply relationships with global medtech and distribution leaders such as GE Healthcare and Cardinal Health provide a durable revenue foundation and underscore the company's credibility as a supplier.

The OEM supply history with 3M across 16 Asian countries serves as an indirect proof of global product quality competitiveness. Holding FDA registration, CE Mark, and ISO 13485 certification reduces the re-certification burden when pursuing new customers in advanced markets, enhancing commercial scalability.

This embedded position in major global supply chains constitutes a meaningful barrier to entry that would be difficult to displace in the short term.

Structural Tailwinds from Biosensor Market Growth

The global biosensors market is projected to grow from approximately USD 32.3 billion in 2024 to USD 68.5 billion by 2034 at a CAGR of roughly 7.9% (GMI Insights).

Chronic disease expansion, aging demographics, and the proliferation of telemedicine and wearable healthcare will continue to drive demand for ECG and SpO2 monitoring products.

This translates into a direct structural growth engine for the disposable medical electrode consumables sub-market in which Bio Protech operates.

Should market growth outpace consensus forecasts, existing OEM contract structures would allow supply volumes to increase organically, amplifying revenue upside without proportional additional investment.

High Export Ratio and Favorable FX Leverage

Generating over 70% of revenues from exports reduces the company's dependence on domestic economic cycles and enables direct participation in global demand growth.

The high proportion of dollar- and yen-denominated export revenues creates a natural FX leverage effect, whereby a sustained period of Korean won weakness enhances translated revenues and profits.

U.S. and China subsidiaries provide a platform for close engagement with global clients and rapid response to procurement requirements.

Further penetration of emerging markets—such as the Middle East, Southeast Asia, and Latin America—could support both quantitative and qualitative improvement in the export revenue base over time.

Bear factors

Extreme Market Illiquidity

The reported daily trading value of KRW 1,292 on the reference date is effectively indistinguishable from a day with no trading at all. The KONEX market structure limits direct retail participation and makes it practically impossible for institutional or foreign investors to gain meaningful exposure.

Under such illiquid conditions, even minimal transaction volumes can cause disproportionate price moves, undermining fair price discovery—reflected in a 52-week price range of KRW 298–660. From an investor standpoint, both entering and exiting a position are effectively infeasible under current market conditions.

Disclosure Limitations and Absence of Analyst Coverage

KONEX-listed companies face lighter periodic disclosure requirements than KOSDAQ or KOSPI peers, limiting the financial and operational data available to outside investors. There is no sell-side coverage and no external analyst reports to provide independent valuation benchmarks.

Key profitability metrics—including operating income, net income, and free cash flow—cannot be reliably verified through publicly available third-party sources. Structural information asymmetry between insiders and external investors is an inherent feature of this market tier and cannot easily be resolved.

Intense Global Competition and Scale Limitations

The medical electrode and biosensor market is intensely contested by large multinationals with vastly superior scale and resources, including 3M, Ambu, Nikomed, and Covidien (Medtronic).

As a specialist manufacturer with roughly 100 employees, Bio Protech faces inherent structural disadvantages in R&D investment capacity, production scalability, and speed of technology adoption.

If dominant competitors intensify price competition or accelerate innovation, the renewal of existing OEM and supply contracts could become uncertain.

Failure to keep pace with the ongoing digitalization of medical devices—such as smart patches, wireless biosignal monitoring, and AI-integrated diagnostics—risks a gradual erosion of product competitiveness over time.

Risk factors

Macro and FX Risk

A global economic downturn or tightening of healthcare spending could lead hospitals and medical institutions to cut disposable consumable procurement budgets, resulting in volume declines and unit price pressure.

Monetary tightening or consumption slowdowns in key export markets such as the U.S. and Europe could delay medical device procurement cycles. Sharp exchange rate fluctuations represent a two-way risk to the Korean-won translation of predominantly dollar-denominated export revenues.

Escalating U.S.-China trade tensions or tightening of medical device import regulations in major markets could directly threaten the company's export-driven revenue structure.

Customer Concentration Risk

Heavy reliance on a small number of global clients such as GE Healthcare and Cardinal Health means that changes in their procurement strategy or contract terminations could have an immediate and severe impact on revenues.

If major global medtech companies pursue supplier consolidation or in-sourcing strategies, or shift business to lower-cost competitors, the sustainability of existing supply volumes would become uncertain.

High dependence on single clients or OEM channels also translates into structural negotiating power disadvantages in pricing discussions. Without visible progress in customer diversification, this risk is unlikely to be resolved on a structural basis.

Regulatory and Certification Risk

As a disposable medical device manufacturer, Bio Protech must continuously meet rigorous certification and renewal requirements set by regulators including the FDA, CE (EU MDR), PMDA (Japan), and NMPA (China).

Regulatory environment changes or product safety incidents could trigger recalls or suspension of sales, posing material threats to business continuity.

The trend toward increased regulatory complexity—such as stricter FDA 510(k) reviews in the U.S.—imposes disproportionate compliance cost burdens on small specialist manufacturers relative to large multinationals.

For the China subsidiary, changes in the NMPA regulatory framework or a deterioration of the operating environment due to geopolitical risks cannot be ruled out.

Overall view

Bio Protech is a specialist medical electrode manufacturer with a credible business model and demonstrated export competitiveness, having embedded itself within the global supply chains of GE Healthcare and Cardinal Health.

Its reported 2024 revenue of approximately KRW 25.1 billion (per third-party data), export revenue share above 70%, and a complete suite of advanced-market regulatory certifications reflect the capabilities of a manufacturer with over 25 years of operating history.

The projected annual growth rate of roughly 7.9–8% for the global biosensors market suggests a structurally favorable medium- to long-term industry backdrop.

However, extreme market illiquidity—with daily trading value of just KRW 1,292 on the reference date—combined with limited public disclosures inherent to the KONEX listing tier, effective barriers to institutional and foreign investor participation, and zero sell-side analyst coverage represent unresolved structural challenges from an investment standpoint.

The inability to independently verify key profitability metrics such as operating income and net income through publicly available sources adds a further layer of uncertainty.

In the absence of a visible catalyst for improving liquidity or a confirmed plan for an upward listing to KOSDAQ or KOSPI, investment accessibility in the stock market is effectively foreclosed regardless of the underlying business quality, warranting a cautious stance at this time.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 6 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.